TrialBMJ open2017

Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).

Masaya Koshizaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.